Clinical Trial Update: An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder [Phase 3]

View source ↗

Summary

Phase 3 randomized study evaluating saredutant in combination with paroxetine for major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Paroxetine (Paroxetine hydrochloride)
• Saredutant (saredutant)

Snippet

Sponsor: Sanofi | Conditions: Depressive Disorder, Major | Phase 3 | Status: COMPLETED